|Jump to:||Authorized Access|||||Attribution|||||Authorized Requests|
- Study Description
The Electronic Medical Records and Genomics (eMERGE) Network is a National Institutes of Health (NIH)-organized and funded consortium of U.S. medical research institutions. The primary goal of the eMERGE Network is to develop, disseminate, and apply approaches to research that combine biorepositories with electronic medical record (EMR) systems for genomic discovery and genomic medicine implementation research. eMERGE was announced in September 2007 and began its third phase in September 2015. eMERGE III consists of nine study sites, two central sequencing and genotyping facilities, and a coordinating center. eMERGE Phase III aims to: 1) sequence and assess the phenotypic implication of rare variants in a custom designed eMERGEseq panel consisting of 109 genes (including 56 ACMG actionable finding list genes and the top 6 genes from each site relevant to their specific aims), as well as approximately 1400 SNPs; 2) assess the phenotypic implications of these variants by developing, validating and implementing new phenotype algorithms, 3) integrate genetic variants into EMRs to inform clinical care; and 4) create community resources. Included in this study are:
- ~ 15,000 eMERGE participants from nine eMERGE III study sites and one study site collaborator.
- Corresponding demographics, body mass index measurements.
- Top PheWAS codes generated from a collated list of ICD codes from all study sites.
Study sites and participants include:
Cincinnati Children's Hospital Medical Center (CCHMC):
Cincinnati Children's Hospital Medical Center (CCHMC) is a not-for-profit hospital and research center pioneering breakthrough treatments, providing outstanding family-centered patient care and training healthcare professionals for the future, and dedicated to improving health and welfare of children and to the shared purpose of discovery and practical application of new genomic information to the ordinary care of children. We bring a comprehensive electronic health record (EPIC), a deidentified i2b2 data warehouse of 680K patient records, a biobank with >261,000 consents that allow return of results to >84,000 patients and guardians who have provided DNA samples, and hundreds of faculty and senior staff who make genomics or informatics an active focus of their research. CCHMC will help the eMERGE III Steering Committee identify genes for the eMERGE III targeted sequencing panel, provide 3,000 DNA samples from CCHMC patients to be sequenced, review targeted gene panels from clinical care at CCHMC for somatic mosaicism and reinterpretation, and further develop and disseminate a software workflow suite for sequence analysis. We will also extend our work generating phenotype algorithms using heuristic and machine learning methods to many new childhood diseases. We will develop tools to evaluate adolescent return of results preferences, examine the ethical and legal obligations and potential to reanalyze results, and develop clinical decision support for phenotyping, test ordering, and returning sequencing results.
Children's Hospital of Philadelphia (CHOP):
The Center for Applied Genomics (CAG) is a specialized Center of Emphasis at the Children's Hospital of Philadelphia (CHOP), and one of the world's largest genetics research programs, with to state-of-the-art high-throughput sequencing and genotyping technology. Our primary goal is to translate basic research findings to medical innovations. We aim to develop new and better ways to diagnose and treat children affected by rare and complex medical disorders, including asthma, autism, epilepsy, pediatric cancer, learning disabilities, and a range of rare diseases. Ultimately, our objective is to generate new diagnostic tests and to guide physicians to the most appropriate therapies. Participants were recruited from the CAG biorepository (n>450,000), specifically from >100,000 CHOP pediatric patients and family members, which is enriched for rare-diseases (n>12,000). Center for Applied Genomics, The Children's Hospital of Philadelphia We gratefully thank all the children and their families who enrolled in this study, and all individuals who donated blood samples for research purposes. Genotyping for this project was performed at the Center for Applied Genomics and supported by an Institutional Development Award from The Children's Hospital of Philadelphia. Sequencing was supported by the National Institutes of Health through an award from the National Human Genome Research Institute's Electronic Medical Records and Genomics (eMERGE) program (U01HG008684).
The goal of the Columbia eMERGE III project is to develop methods for integrating genomic data in EHRs and to study the impact of such genomic informatics interventions on the health of a diverse, underserved urban adult English- and Spanish-speaking patient population in Northern Manhattan served by Columbia University Medical Center/New York-Presbyterian Hospital system. The study group is 2500 patients recruited from diverse clinics and community outreach centers of self-reported White (~61%), Asian (~11%), African-American (~11%), American Indian/Alaska Native (<1%) racial and Hispanic (~33%) ethnic backgrounds. There are two subgroups in the study cohort - a retrospective group (N=1052) that includes patients from oncology and nephrology clinics, and a prospective one (N=1448) that includes healthy individuals as well as participants with diverse medical conditions. Confirmed pathogenic variants in 70 selected genes will be returned to participants and their healthcare providers through the EHR integration. Participants are able to choose the results they receive and will have the freedom to meet with a genetic counselor and a geneticist to review results. The impact of genetic testing on clinical care is determined by periodic monitoring of EHRs.
Samples and phenotype data in this study were provided by the Geisinger MyCode® Community Health Initiative. Participants are recruited across the Geisinger System via online consents or in-person consents at a hospital or clinic visit. Enrollment is ongoing with over 100,000 individuals currently consented.
Partners Healthcare (Harvard University):
The Partners HealthCare Biobank is a large research program designed to help researchers understand how people's health is affected by their genes, lifestyle, and environment. This large research data and sample repository provides access to high-quality, consented blood samples to help foster research, advance our understanding of the causes of common diseases, and advance the practice of medicine. For the Partners research community (Massachusetts General Hospital and Brigham and Women's Hospital), the Biobank provides:
- Banked samples (plasma, serum, and DNA) collected from consented patients
- Blood samples that were discarded after clinical testing in the Crimson Cores maintained in the Brigham and Women's Hospital and Massachusetts General Hospital Pathology Departments
- Sample handling and preparation services
- Link to the biobank data to the Partners Research Patient Data Registry (RPDR) a research instance of our electronic clinical chart
- Data access through our research portal.
To date, over 70,000 Partners patients have given their consent to enroll, give a blood sample, receive research results and agreed to be re-contacted for additional research studies. The Biobank has enabled Partners investigators to compete for nationally recognized grants in personalized medicine such as a clinical electronic Medical Records and Genomics network (eMERGE) site and the national All of US program. The Biobank currently supports over 120 Partners investigators and over 130 million dollars in NIH research.
Kaiser Permanente Washington/ (KPWA) / University of Washington (UW):
KPWA participants were enrolled in the eMERGE Network through the Northwest Institute of Genetic Medicine (NWIGM) biorepository, and provided the appropriate consent to receive clinically relevant genetic results (N=2,500.) NWIGM is based at the University of Washington and co-managed by the University of Washington and KPWA. The purpose of the NWIGM biorepository is to build infrastructure and resources to carry out a broad range of future genetic research. KPWA members enrolled in the biorepository are asked to provide informed consent to providing a DNA sample for storage in the NWIGM biorepository. The consent is purposefully broad to serve the dual purpose of reducing the burden on researchers who wish to use this biorepository and the IRB committees who will be responsible for reviewing these requests in the future. Participants were eligible if aged 50 - 65 years old at the time of their enrollment into the NWIGM repository, living, enrolled in KPWA's integrated group practice, and had completed an online Health Risk Appraisal. The selection algorithm was based on several data sources from the EHR at KPWA. 1) Demographics - participants with self-reported race as Asian ancestry were prioritized and selected to enrich for non-European ancestry. The KPWA eMERGE cohort includes N=1,245 members of Asian ancestry. 2) Participants were also selected for a history of colorectal cancer (N=1,255), in order to allow us to enrich germline pathogenic variants.
The Return of Actionable Variants Empirical (RAVE) Study was approved by the Mayo Clinic IRB. We recruited 2537 participants from Mayo Clinic biobanks in Rochester, MN, who had hypercholesterolemia or colon polyps, thereby enriching for Familial hypercholesterolemia (FH) and monogenic causes of colorectal cancer (CRC). Additional eligibility criteria were: 1) residents of Southeast MN who were alive and aged 18-70 years; 2) LDL-C level >155 or >120 mg/dl while on lipid-lowering therapy; 3) no known cause of secondary hyperlipidemia; and 4) no cognitive impairment or dementia that would compromise their ability to give written informed consent. Based on these criteria, we identified 5270 eligible patients and obtained informed consent from 3030 participants. Recruitment was conducted in waves and utilized mailed recruitment packets consisting of a study brochure, a written informed consent form, a baseline psychosocial questionnaire, and a return postage-paid envelope. DNA of 2537 participants was sent for CLIA-certified targeted sequencing of 109 genes including genes associated with FH and CRC. Targeted sequencing and genotyping was performed in a Central Laboratory Improvement Amendment (CLIA)-certified laboratory.
Samples and data used in this study were obtained from patients from Northwestern Medicine, an integrated healthcare system, formed through a partnership of Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine. Participants include a retrospective cohort from the Northwestern Pharmacogenomics Study, funded through the eMERGE II project, NHGRI (3U01HG006388-02S1) and a prospective cohort from the Genetic Testing and Your Health Study, funded through the eMERGE III project, NHGRI (U01HG008673). Patients were eligible to participate if they were18 years or older and see a physician at Northwestern Medicine. Patients consented to genetic testing and to allow their results to be placed in their electronic medical record.
Vanderbilt University Medical Center:
Vanderbilt University Medical Center (VUMC) participants were enrolled in the eMERGE Network through the Vanderbilt Genome-Electronic Records (VGER) project. Patients were provided the appropriate consent to receive clinically relevant genetic results (N=2,700). Participants were eligible if aged 21 or over, had a healthcare provider at VUMC, and visited the provider at least 3 times in the past 3 years.
Study site collaborator and participants include:
Meharry Medical College:
Inclusion of ethnic groups in genomic research is critical to identify possible reasons for health disparities. African-Americans are being enrolled in various outpatient clinics of Nashville General Hospital at Meharry, an inner city hospital primary serving a poorer patient group. A total of 500 African Americans with four cancer types demonstrating health disparities in this population - prostate, colon, breast, lung are identified and approached by clinical research coordinators. The purpose of the study is to determine if any genetic information can be identified from these patients who have or are at high risk of one of these disparate cancers. All participants provide written informed consent and HIPAA authorization to provide blood samples for broad research use and permission to access data in their hospital electronic medical record for research now and in the future. An extensive demographic profile is obtained and entered into a REDCap database. Blood samples are obtained for a panel of alleles from extracted DNA at Baylor. In addition, de-identified coded samples are processed and stored in a central biorepository for further DNA, RNA and proteomic analyses. The survey and phlebotomy are performed at the time of the initial contact and agreement to participate. Nearly all patients approached willingly agree to participate for potential benefit to themselves, family members, or humankind. Little concern is voiced of providing samples for genetic analysis. Study investigators will share results with the participants and providers if testing does not indicate high risk. Results indicating increased risk or actionable alleles for the patient and/or family will be returned by a genetic counselor. Monitoring of the patients' health in this cohort will continue to be followed in the EMR to identify any future associations that might explain health disparities in African Americans. Proposals will be reviewed from investigators to study the genetic or proteomic samples as well as the clinical and demographic information in the repository.
Please note that this version of the dataset has a handful of mismatches between genotyped and provided sex, discovered after posting of the data. They will be removed from the version 2 dataset that is forthcoming. Data with the following IDs should be removed:
42025287 42137441 42139915 42284933 42412243 42456938 42456946 42672223 42954000 49368913 49868431 52111929 63312723 68877688 81014537 81014938 81014945 81014946 81014959 81015004 81015025 81015050 81015218 81015243 81015316 81015330 81015374 81015436 81015438 81015662 81015668 81015776 81015778
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Total number of consented subjects: 15700
- Subject Sample Telemetry Report (SSTR)
- Authorized Access
- Publicly Available Data (Public ftp)
- Molecular Data
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Targeted Sequencing The Partners HealthCare Laboratory for Molecular Medicine (LMM) and the Broad In Partners-Broad eMERGEseq Panel N/A N/A Not a commercially available product. Please contact Dr. Heidi Rehm (firstname.lastname@example.org) or visit www.gwas.org, for more information on the custom-designed product. Targeted Sequencing Baylor College of Medicine Human Genome Sequencing Center HGSC_eMERGESeq_V2 N/A N/A Not a commercially available product. Please contact Donna Muzny (email@example.com) or visit www.gwas.org, for more information on the custom-designed product.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
- Links to Related Resources
- Authorized Data Access Requests
- Study Attribution
Principal Investigators, Phase III Study Site
- Hakon Hakonarson, MD, PhD. Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- John Harley, MD, PhD. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- Chunhua Weng, PhD, MS. Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA.
- Ali Gharavi, MD. Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA.
- George Hripcsak, MD, MS. Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA.
- Marc Williams, MD. Geisinger Health, Danville, PA, USA.
- Elizabeth Karlson, MD. Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.
- Shawn Murphy, MD, PhD. Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.
- Jordan Smoller, MD, ScD. Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.
- Scott Weiss, MD, MS. Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.
- Eric Larson, MD, MPH. Kaiser Permanente Washington with the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Gail Jarvik, MD, PhD. Kaiser Permanente Washington with the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- Iftikhar Kullo, MD. Mayo Clinic, Rochester, MN, USA.
- Richard Sharp, PhD. Mayo Clinic, Rochester, MN, USA.
- Rex Chisholm, PhD. Northwestern University, Chicago, IL, USA.
- Maureen Smith, MS. Northwestern University, Chicago, IL, USA.
- Dan Roden, MD. Vanderbilt University Medical Center, Nashville, TN, USA.
- Josh Denny, MD, MS. Vanderbilt University Medical Center, Nashville, TN, USA.
Principal Investigator, Phase III Coordinating Center
- Josh Peterson, MD, MPH. Vanderbilt University Medical Center, Nashville, TN, USA.
Principal Investigators, Phase III Clinical Sequencing Center
- Heidi Rehm, PhD. The Partners HealthCare Laboratory for Molecular Medicine (LMM) and the Broad Institute, Cambridge, MA, USA.
- Niall Lennon, PhD. The Partners HealthCare Laboratory for Molecular Medicine (LMM) and the Broad Institute, Cambridge, MA, USA.
- Richard Gibbs, PhD. Baylor College of Medicine Human Genome Sequencing Center, Houston, TX, USA.
Principal Investigator, Phase III Study Site Collaborator
- Samuel Adunyah, PhD. Meharry Medical College, Nashville, TN, USA.
Funding Source, Phase III Study Site
- U01HG8684. Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- U01HG8666. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
- U01HG8680. Columbia University Medical Center/New York Presbyterian Hospital, New York, NY, USA.
- U01HG8679. Geisinger Health, Danville, PA, USA.
- U01HG8685. Harvard Medical School, Brigham and Women's Hospital, Massachusetts General Hospital, Partners HealthCare Personalized Medicine, Cambridge, MA, USA.
- U01HG8657. Kaiser Permanente Washington with the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
- U01HG6379. Mayo Clinic, Rochester, MN, USA.
- U01HG8673. Northwestern University, Chicago, IL, USA.
- U01HG8672. Vanderbilt University Medical Center, Nashville, TN, USA.
Funding Source, Phase III Coordinating Center
- U01HG8701. Vanderbilt University Medical Center, Nashville, TN, USA.
Funding Source, Phase III Clinical Sequencing Center
- U01HG8676. The Partners HealthCare Laboratory for Molecular Medicine (LMM) and the Broad Institute, Cambridge, MA, USA.
- U01HG8664. Baylor College of Medicine Human Genome Sequencing Center, Houston, TX, USA.
Funding Source, Phase III Study Site Collaborator
- U54MD007593-10. Meharry Medical College, Nashville, TN, USA.
- Principal Investigators, Phase III Study Site